Original Article

STI Testing among Medicaid Enrollees Initiating PrEP for HIV Prevention in Six Southern States

Authors: Paul Lanier, PhD, Susan Kennedy, MPP, MSW, Angela Snyder, PhD, Jessica Smith, PhD, Eric Napierala, MA, Jeffrey Talbert, PhD, Lindsey Hammerslag, PhD, Larry Humble, PharmD, PhD, Eddy Myers, MBA, Angel Whittington, MPA, Jheramy Smith, BBA, Marcus Bachhuber, MD, Anna Austin, PhD, Thomas Blount, MPH, Grace Stehlin, MS, Ana Lopez-De Fede, PhD, Hoa Nguyen, PhD, Jean Bruce, BS, Carlos G. Grijalva, MD, Sunita Krishnan, MPH, Caitlin Otter, BA, Katie Horton, PhD, JD, Naomi Seiler, JD, William S. Pearson, PhD


Objectives: The purpose of this study was to measure sexually transmitted infection (STI) testing among Medicaid enrollees initiating preexposure prophylaxis (PrEP) to prevent human immunodeficiency virus. Secondary data are in the form of Medicaid enrollment and claims data in six states in the US South.

Methods: Research partnerships in six states in the US South developed a distributed research network to accomplish study aims. Each state identified all first-time PrEP users in fiscal year 2017–2018 (combined N = 990) and measured the presence of STI testing for chlamydia, syphilis, and gonorrhea through 2019. Each state calculated the percentage of individuals with at least one STI test during 3-, 6-, and 12-month follow-up periods.

Results: The proportion of first-time PrEP users that received an STI test varied by state: 37% to 67% of all of the individuals in each state who initiated PrEP received a test within the first 6 months of PrEP treatment and 50% to 77% received a test within the first 12 months.

Conclusions: Although the Centers for Disease Control and Prevention recommends STI testing at least every 6 months for PrEP users, our analysis of Medicaid data suggests that STI testing occurs less frequently than recommended in populations at elevated risk of syphilis, gonorrhea, and chlamydia.
Posted in: Infectious Disease136 Acquired Immunodeficiency Syndrome (AIDS) And Human Immunodeficiency Virus (HIV) Infection17

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.


1. Centers for Disease Control and Prevention. HIV surveillance report: diagnoses of HIVinfection in the United States and dependent areas 2019. https://www.cdc.gov/hiv/library/reports/hiv-surveillance/vol-32/index.html. Published May 2021. Accessed February 26, 2023.
2. US Department of Health and Human Services. HIV national strategic plan for the United States: a roadmap to end the epidemic 2021–2025. https://files.hiv.gov/s3fs-public/HIV-National-Strategic-Plan-2021-2025.pdf. Published 2021. Accessed February 26, 2023.
3. US Preventive Services Task Force; Owens DK, Davidson KW, et al. Preexposure prophylaxis for the prevention of HIV infection: US Preventive Services Task Force recommendation statement. JAMA 2019;321:2203–2213.
4. Chou R, Evans C, Hoverman A, et al. Preexposure prophylaxis for the prevention of HIV infection: evidence report and systematic review for the US Preventive Services Task Force. JAMA 2019;321:2214–2230.
5. Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2019. https://www.cdc.gov/nchhstp/newsroom/2021/2019-std-surveillance-report-press-release.html. Published 2021. Accessed February 26, 2023.
6. Galvin SR, Cohen MS. The role of sexually transmitted diseases in HIV transmission. Nat Rev Microbiol 2004;2:33-42.
7. Wasserheit J, Epidemiological synergy. Interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases. Sex Transm Dis 1992;19:61-77.
8. Centers for Disease Control and Prevention; US Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States—2017 update: a clinical practice guideline. https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2017.pdf. Published March 2018. Accessed February 26, 2023.
9. Quaife M, MacGregor L, Ong JJ, et al. Risk compensation and STI incidence in PrEP programmes. Lancet HIV 2020;7:e222-e223.
10. Traeger MW, Schroeder SE, Wright EJ, et al. Effects of pre-exposure prophylaxis for the prevention of human immunodeficiency virus infection on sexual risk behavior in men who have sex with men: a systematic review and meta-analysis. Clin Infect Dis 2018;67:676-686.
11. Ramchandani MS, Golden MR. Confronting rising STIs in the era of PrEP and treatment as prevention. Curr HIV/AIDS Rep 2019;16:244-256.
12. Jenness SM, Weiss KM, Goodreau SM, et al. Incidence of gonorrhea and chlamydia following human immunodeficiency virus preexposure prophylaxis among men who Have sex with men: a modeling study. Clin Infect Dis 2017; 65:712-718.
13. Chang BA, Pearson WS, Owusu-Edusei K. Correlates of county-level nonviral sexually transmitted infection hot spots in the US: application of hot spot analysis and spatial logistic regression. Ann Epidemiol 2017;27:231-237.
14. Adimora AA, Schoenbach VJ. Social context, sexual networks, and racial disparities in rates of sexually transmitted infections. J Infect Dis 2005; 191(suppl 1):S115-S122.
15. Kaiser Family Foundation. Medicaid’s role for women. https://firstfocus.org/wp-content/uploads/2019/11/Fact-Sheet-Medicaids-Role-for-Women.pdf. Published March 2019. Accessed February 26, 2023.
16. Kay ES, Pinto RM. Is insurance a barrier to HIV preexposure prophylaxis? Clarifying the issue. Am J Public Health 2020;110:61-64.
17. Sullivan PS, Mena L, Elopre L, et al. Implementation strategies to increase PrEP uptake in the South. Curr HIV/AIDS Rep 2019;16:259-269.
18. Siegler AJ, Mouhanna F, Giler RM, et al. The prevalence of pre-exposure prophylaxis use and the pre-exposure prophylaxis-to-need ratio in the fourth quarter of 2017 United States. Ann Epidemiol 2018;28:841-849.
19. Kaiser Family Foundation. Status of state Medicaid expansion decisions: interactive map. https://www.kff.org/medicaid/issue-brief/status-of-state-medicaid-expansion-decisions-interactive-map/. Published February 16, 2023. Accessed February 26, 2023.
20. Adams L, Kennedy S, Allen L, et al. Innovative solutions for state Medicaid programs to leverage their data, build their analytic capacity, and create evidence-based policy. EGEMS (Wash DC) 2019;7:41.
21. Medicaid Outcomes Distributed Research Network (MODRN); Brown E, Schutze M, et al. Use of medications for treatment of opioid use disorder among US Medicaid enrollees in 11 states, 2014–2018. JAMA 2021;326: 154-164.
22. Chan PA, Seiler N, Chu CT. Leveraging Medicaid to enhance preexposure prophylaxis implementation efforts and ending the HIV epidemic. Am J Public Health 2020;110:65-66.
23. Wu H, Mendoza MCB, Huang Ya-Lin A, et al. Uptake of HIV preexposure prophylaxis among commercially insured persons—United States, 2010–2014. Clin Infect Dis 2017;64:144-149.
24. Karletsos D, Stoecker C. Impact of Medicaid expansion on PrEP utilization in the US: 2012–2018. AIDS Behav 2021;25:1103-1111.
25. Chan SS, Chappel AR, Maddox KEJ, et al. Pre-exposure prophylaxis for preventing acquisition of HIV: a cross-sectional study of patients, prescribers, uptake, and spending in the United States, 2015–2016. PLoS Med 2020; 17:e1003072.
26. Smith DK, Van Handel M, Grey J. Estimates of adults with indications for HIV pre-exposure prophylaxis by jurisdiction, transmission risk group, and race/ethnicity, United States, 2015. Ann Epidemiol 2018;28:850-857.e9.
27. Pearson WS, Tao G, Gift TL. Improvement still needed in sexually transmitted disease testing among HIV-positive Medicaid enrollees. Sex Transm Dis 2018; 45:49.
28. Tao G, Pearson WS, Sullivan JM, et al. STI testing and prevalence before and after PrEP initiation among males aged ≥18 years in US private settings. Sex Transm Dis 2021;48:515-520.